Nika Pharmaceuticals, INC
Market Movers (8-K)
OQB
Nika Pharmaceuticals terminated its engagement with OLAYINKA OYEBOLA & CO and hired Boladale Lawal & Co as its new independent accountant.
OQB
Nika Pharmaceuticals has engaged OLAYINKA OYEBOLA & CO as their new independent accountant, effective September 23, 2024.
OQB
Nika Pharmaceuticals, Inc. has cancelled its acquisition of Nika Pharmaceuticals, Ltd., and its independent accountant has resigned, leading to a search for a new auditor.
Worse than expected
Delay expected
OQB
Nika Pharmaceuticals, Inc. has acquired 100% ownership of Nika Pharmaceuticals, Ltd., gaining control of a production facility and land valued at $2.045 million.
OQB
Nika Pharmaceuticals has completed the acquisition of a 40% stake in Nika Europe Ltd., bringing its total ownership to 80%, and acquired four new drug and supplement technologies.
OQB
Nika Pharmaceuticals, Inc. has completed a market extension merger with Nika BioTechnology, Inc., effective March 1, 2024, consolidating operations and streamlining investment.
Delay expected
Quarterly Earnings (10-Q)
OQB
Nika Pharmaceuticals, Inc. reported its Q1 2026 financial results, detailing a net loss and ongoing reliance on related party financing, while also highlighting strategic agreements and operational developments.
Worse than expected
Capital raise
OQB
Nika Pharmaceuticals reports reduced net losses and cash burn in Q3 2025, alongside ongoing pharmaceutical factory development and significant related party transactions.
Better than expected
Capital raise
Delay expected
OQB
Nika Pharmaceuticals, Inc. reported reduced net losses and increased cash for Q2 2025, but faces going concern doubts and internal control deficiencies.
Capital raise
Worse than expected
Delay expected
OQB
Nika Pharmaceuticals reports a reduced net loss for the quarter ended March 31, 2025, as it continues to execute its strategic business plan.
Better than expected
OQB
Nika Pharmaceuticals reported its Q3 2024 results, showing a net loss and ongoing efforts to establish its pharmaceutical manufacturing capabilities.
Worse than expected
Delay expected
OQB
10-Q/A: Nika Pharmaceuticals Reports Q2 2024 Results, Navigates Complex Acquisitions and Restructuring
Nika Pharmaceuticals' Q2 2024 report reveals a period of significant activity including mergers, acquisitions, and strategic shifts, alongside a net loss and ongoing going concern challenges.
Worse than expected
Delay expected
Capital raise
Annual Reports (10-K)
OQB
Nika Pharmaceuticals' latest 10-K filing reveals significant financial distress, including a going concern warning and ineffective internal controls, despite a reduced net loss.
Worse than expected
Capital raise
Delay expected
OQB
Nika Pharmaceuticals' 2024 Form 10-K reveals a net loss increase to $95,792, alongside strategic shifts including a common control merger and OTCQB uplisting.
Capital raise
Worse than expected
OQB
10-K: Nika Pharmaceuticals Reports Full Year 2023 Results, Focuses on Growth and Strategic Partnerships
Nika Pharmaceuticals reported a net loss of $64,833 for 2023, a significant decrease from the $3,183,715 loss in 2022, as the company transitions its business focus towards pharmaceutical and dietary supplement development.
Worse than expected
Capital raise
Insider Trading (Form 4)
OQB
Dimitar Slavchev Savov, CEO, CFO, and President of NIKA Pharmaceuticals, purchased 2,000,000 shares of common stock at $0.25 per share on March 18, 2025.
OQB
NIKA Pharmaceuticals, Inc. reports the acquisition of 145,000,000 shares of common stock by a 10% owner through an LLC.
Better than expected
OQB
Form 4: NIKA Pharmaceuticals, Inc.: NIKA PHARMACEUTICALS, INC Reports Changes in Beneficial Ownership
NIKA PHARMACEUTICALS, INC reports transactions involving preferred and common stock, including acquisitions, disposals, and a forward stock split.